These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-002547-27 Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease 2017-12-31 due-trials
Reported results 2005-001209-24 A double-blind, placebo controlled parallel group pilot study of the effectiveness of D-cycloserine in reducing craving during cue-exposure therapy in abstinent alcohol dependent subjects. 2009-02-27 due-trials
Reported results 2006-000216-24 Serotonin sensitivity in insomnia: a placebo-controlled crossover study of sleep after 5HT2 blockade in primary insomnia. 2009-01-05 due-trials
Reported results 2006-001085-17 Further development of a new model of GAD: The effect of a clinically effective and non−effective dose of lorazepam on CO2 induced anxiety 2008-08-29 due-trials
Reported results 2006-001723-19 AN OPEN LABEL, SINGLE CENTRE PILOT STUDY TO EVALUATE THE KINETICS OF THE SYSTEMIC B-CELL IMMUNE RESPONSE TO A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN HEALTHY ADULTS 2007-04-30 due-trials
Reported results 2008-000971-15 Evaluation of the effects of chronic treatment with venlafaxine (150 mg) and pregabalin (200 mg) on emotional indices of anxiety and panic induced by breathing carbon dioxide. 2009-08-26 due-trials
Reported results 2008-004820-22 Alcohol detoxification in primary care treatment (ADEPT) - a feasibility study of conducting a randomised trial in primary care comparing two pharmacological regimens. 2011-01-31 due-trials
Reported results Terminated 2011-001224-37 Mistletoe in early Breast Cancer (MBC): A pilot study for a randomised controlled trial 2017-12-04 due-trials
Reported results Terminated 2011-001571-39 Investigating the relationship between sleep disturbance and learning in children with Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS): A Randomised Double-Blind Placebo-Controlled Cr... 2014-11-21 due-trials
Reported results 2011-004169-34 Effects of Varenicline and Cognitive Bias Modification on Neural Response to Smoking Cues 2014-07-01 due-trials
Reported results 2012-000090-23 Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial 2017-12-19 due-trials
Reported results 2012-000851-15 What is the clinical and cost effectiveness of oral steroids in the treatment of acute lower respiratory tract infection (LRTI)? A placebo controlled randomised trial 2016-11-24 due-trials
Reported results 2013-003001-26 Choice Of Moisturiser in Eczema Treatment (COMET): A feasibility study of pragmatic, single blind, randomised clinical trial to compare the clinical and cost effectiveness of leave-on emollients in tr... 2016-02-24 due-trials
Reported results 2014-004016-11 What is the clinical and cost effectiveness of benzocaine/phenazone ear drops for reducing antibiotic consumption and ear pain in children aged between 6 months and 10 years presenting to primary care... 2019-03-19 due-trials
Other 2015-002027-26 TARGETING DOPAMINE TO TREAT IMPAIRED MEMORY CONSOLIDATION IN NEURODEGENERATIVE DISEASE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL not-yet-due
Other 2017-000688-34 The Best Emollient for Eczema (BEE) trial: a randomised trial comparing the effectiveness of four commonly prescribed emollients for children with eczema not-yet-due
Reported results 2017-003084-34 The pharmacological effects of granulocyte-colony stimulating factor (GCSF) on frataxin expression in patients with Friedreich Ataxia 2019-04-12 due-trials
Reported results 2017-003635-10 Immediate oral, immediate topical or delayed oral antibiotics for acute otitis media with discharge (the Runny Ear STudy: REST) 2019-10-31 due-trials
Other 2018-000279-34 Mistletoe And Breast Cancer (MAB): A pilot study for a randomized double-blind controlled trial not-yet-due
Other 2018-003219-23 CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease not-yet-due